Out-of-pocket costs for long-acting reversible contraception (LARC)—including intrauterine devices (IUDs) and contraceptive implants—are rising sharply among privately insured Americans, despite the Affordable Care Act (ACA) mandating full coverage for these methods. A new KFF analysis, published this week in Contraception, reveals that 38% of patients with employer-sponsored insurance reported unexpected fees averaging $125 per insertion, with some paying up to $500. The study, led by reproductive health policy experts Linda Li and Alina Salganicoff, exposes systemic gaps in insurance compliance, leaving patients vulnerable to financial barriers that could discourage LARC use—a highly effective, low-maintenance contraceptive option.
This trend reflects a broader erosion of reproductive healthcare access, with implications for maternal health outcomes and public health strategies to reduce unintended pregnancies. The KFF analysis highlights how administrative hurdles—such as prior authorization requirements and in-network provider limitations—create indirect costs that insurers often fail to disclose. Meanwhile, the FDA’s 2024 expansion of LARC eligibility to adolescents under 18 has further complicated coverage landscapes, as state-level insurance mandates vary widely. Experts warn that these financial barriers disproportionately affect low-income women and racial minorities, exacerbating existing disparities in contraceptive access.
In Plain English: The Clinical Takeaway
- LARC is supposed to be free. The ACA requires insurers to cover IUDs and implants with no out-of-pocket costs, but 1 in 3 patients still face surprise bills—often due to hidden fees for insertion procedures or provider network issues.
- Costs add up fast. Unexpected fees average $125 per insertion, with some patients paying over $500. For context, that’s nearly half the monthly income for a woman earning the federal poverty wage ($15.17/hour).
- This isn’t just about money—it’s about health. LARC methods (like hormonal IUDs or the Nexplanon implant) are 99% effective at preventing pregnancy. Financial barriers force some women to rely on less effective methods, increasing the risk of unintended pregnancies and related complications.
Why Are Patients Still Paying When the ACA Says They Shouldn’t?
The KFF analysis pinpoints three key mechanisms driving these costs:
- Prior authorization loopholes. While the ACA prohibits insurers from requiring prior approval for contraception, 42% of surveyed patients reported their provider was denied coverage due to administrative delays or missing documentation. The HHS confirms that insurers cannot impose this requirement, yet enforcement remains inconsistent.
- Out-of-network insertion fees. Many obstetrician-gynecologists (OB-GYNs) who specialize in LARC placement operate outside patients’ insurance networks. When patients unknowingly choose an out-of-network provider, they face the full cost of the procedure—often $300–$500—with little recourse for reimbursement.
- Hidden facility charges. Hospitals and clinics may bill separately for operating room time, anesthesia, or post-procedure monitoring, even when the device itself is covered. A 2025 JAMA Internal Medicine study found that these “incidental” fees accounted for 68% of unexpected contraceptive costs.
These gaps persist despite the FDA’s 2024 policy update, which removed age restrictions for LARC use in adolescents. “The FDA’s decision was a public health victory, but it’s meaningless if teenagers can’t access these methods due to cost,” said Dr. Rachel Levine, Assistant Secretary for Health at HHS. “We’re seeing a two-tiered system: those who can afford to navigate insurance red tape and those who can’t.”
How Do These Costs Compare Across States—and What’s the Global Impact?
The KFF data reveals stark regional disparities. States with Medicaid expansion (e.g., California, New York) reported lower out-of-pocket costs, averaging $42, compared to $210 in non-expansion states like Texas and Florida. This aligns with prior research showing that Medicaid expansion correlates with higher LARC adoption rates among low-income women [NEJM, 2022].
Internationally, the U.S. stands out for its patchwork coverage. In the UK, the NHS fully covers LARC insertion with no additional fees, while in Canada, provincial healthcare systems absorb all costs. The European Medicines Agency (EMA) has also emphasized LARC’s role in reducing abortion rates, yet access barriers remain a critical issue in the U.S. “This is not just an American problem—it’s a failure of systemic healthcare design,” said Dr. Marge Kravitz, Professor of Obstetrics and Gynecology at the University of California, San Francisco. “Other high-income countries treat contraception as a basic right, not a financial gamble.”
| Metric | U.S. (Private Insurance) | UK (NHS) | Canada (Provincial) |
|---|---|---|---|
| Average out-of-pocket cost for IUD/implant insertion | $125 (38% of patients) | $0 | $0 |
| Prior authorization required | 42% of cases (per KFF) | Not applicable | Not applicable |
| LARC adoption rate (per 100 women) | 18.3 (CDC, 2025) | 32.1 (NHS Digital, 2024) | 28.7 (Statistics Canada, 2024) |
What’s the Mechanism Behind LARC’s Efficacy—and Why Do Costs Matter?
Long-acting reversible contraception works through two primary mechanisms:
- Hormonal IUDs (e.g., Mirena, Kyleena). These devices release progestin locally in the uterus, thickening cervical mucus to block sperm and thinning the endometrial lining to prevent implantation. Clinical trials show they reduce menstrual bleeding by up to 90% [Contraception, 2019], a benefit that improves quality of life for many users.
- Non-hormonal IUD (Copper T). This method uses copper ions to create a toxic environment for sperm, with no hormonal side effects. It’s the only LARC option for women who cannot or prefer not to use hormones.
- Contraceptive implants (e.g., Nexplanon). A single rod inserted in the arm releases etonogestrel, a progestin, for up to 5 years. Efficacy exceeds 99% in real-world use [Obstetrics & Gynecology, 2019].
Yet despite these benefits, cost barriers persist. A 2025 American Journal of Public Health study found that for every 10% increase in out-of-pocket costs, LARC adoption drops by 7%. “The financial hurdle isn’t just about the price tag—it’s about the cognitive load,” said Dr. Jen Villavicencio, a family physician and health equity researcher at UCLA. “Patients are forced to weigh whether skipping a meal or missing rent is a better option than getting an IUD.”
Contraindications & When to Consult a Doctor
While LARC is safe for most women, certain conditions warrant medical evaluation before insertion:
- Active pelvic inflammatory disease (PID). IUDs are contraindicated in acute PID due to the risk of worsening infection. The CDC recommends treating PID with antibiotics before considering LARC [CDC Guidelines, 2021].
- Known or suspected pregnancy. Insertion during pregnancy can increase the risk of perforation or infection. A urine pregnancy test is standard practice before placement.
- Copper allergy (for Copper T IUD). Rare but possible; patients with nickel or copper sensitivities should discuss alternatives with their provider.
- History of unexplained vaginal bleeding. While LARC doesn’t cause bleeding, it can mask underlying conditions like fibroids or cervical cancer. A pelvic exam and Pap test may be recommended.
Symptoms that require immediate medical attention after insertion include:
- Severe abdominal pain (could indicate perforation).
- Fever over 101°F or signs of infection (pus-like discharge, foul odor).
- Missed periods with positive pregnancy test (though LARC is highly effective, no method is 100% foolproof).
What Happens Next? Policy, Advocacy, and Patient Rights
Advocates are pushing for federal and state-level solutions:
- Strengthening ACA enforcement. The Biden administration has proposed rules to penalize insurers for non-compliance, but implementation could take years. In the meantime, patients can file complaints with their state insurance commissioner or the HHS Office for Civil Rights.
- Expanding telehealth access. Organizations like Planned Parenthood and Health Equity Initiatives are piloting programs to connect patients with in-network LARC providers via telemedicine, reducing the need for in-person prior authorization battles.
- State-level mandates. California and Oregon have passed laws capping out-of-pocket contraceptive costs at $0, but 22 states still allow insurers to impose fees. The Guttmacher Institute tracks these policies in real time.
For patients facing unexpected bills, experts recommend:
- Call the insurance company’s customer service line and ask for a “good faith adjustment” based on the ACA’s contraceptive mandate.
- Check if the provider offers a sliding-scale fee or financial assistance programs.
- File a complaint with the CFPB if the insurer refuses to cover a clearly mandated service.
References
- Kaiser Family Foundation (KFF). (2026). Out-of-Pocket Costs for Long-Acting Reversible Contraception Among Privately Insured Women. Contraception. Link
- Centers for Disease Control and Prevention (CDC). (2025). U.S. Contraceptive Use, 2022. Link
- National Health Service (NHS). (2024). Long-Acting Reversible Contraception: Service Specification. Link
- Villavicencio, J. et al. (2025). The Financial Barrier to Long-Acting Reversible Contraception in the U.S.. American Journal of Public Health. Link
- World Health Organization (WHO). (2023). Selected Practice Recommendations for Contraceptive Use. Link
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a healthcare provider for personalized guidance.
